Evidence map›Paper›PMID 34337026›Full record

ArticleBioMed research international2021

Tumor Immune Microenvironment Characterization of Primary Lung Adenocarcinoma and Lymph Node Metastases.

Yuan Zhou, Xinying Shi, Huan Chen, Beibei Mao, Xue Song, Lingling Gao, Jiao Zhang, Ying Yang, Henghui Zhang, Guo Wang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuan ZhouDepartment of Thoracic Surgery, Xiangya Hospital of Central South University, 410008 Changsha, Hunan, China.
Xinying ShiBeijing Genecast Biotechnology Co., Beijing, China.
Huan ChenBeijing Genecast Biotechnology Co., Beijing, China.
Beibei MaoBeijing Genecast Biotechnology Co., Beijing, China.
Xue SongBeijing Genecast Biotechnology Co., Beijing, China.
Lingling GaoBeijing Genecast Biotechnology Co., Beijing, China.
Jiao ZhangBeijing Genecast Biotechnology Co., Beijing, China.
Ying YangBeijing Genecast Biotechnology Co., Beijing, China.
Henghui ZhangBeijing Genecast Biotechnology Co., Beijing, China.
Guo WangDepartment of Clinical Pharmacology, Xiangya Hospital of Central South University, 410008 Changsha, Hunan, China.ORCID https://orcid.org/0000-0002-8359-9076
Wei ZhuangDepartment of Thoracic Surgery, Xiangya Hospital of Central South University, 410008 Changsha, Hunan, China.ORCID https://orcid.org/0000-0003-3395-8840
Genecast (China) · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe essential roles of the tumor microenvironment (TME) have been recognized during the initiation and progression of primary lung adenocarcinoma (LUAD). The aim of the present study was to delineate the immune landscape in both primary cancer and matched lymph node metastasis from a cohort of locally advanced stage LUAD patients with distinct outcomes.

methodsFormalin-fixed, paraffin-embedded samples were collected from 36 locally advanced LUAD patients. Transcriptome data of the tumor immune microenvironment were resolved using an immune oncology panel RNA sequencing platform. Bioinformatics approaches were used to determine the differentially expressed genes (DEGs), dysregulated pathways, and immune cell fraction between patients with early recurrence (ER) and late recurrence (LR).

resultsHere, we showed that in primary cancer tissues, 23 DEGs were obtained between patients with ER and LR. Functional analysis revealed that the LR in LUAD patients may be associated with enriched gene sets belonging to the antigen presentation and MHC protein complex, innate immune response, and IFN-

conclusionsIn LUAD, the enrichment in antigen presentation, MHC protein complex, and IFN-

Indexed as

Adenocarcinoma of LungAdultAgedFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsLymphatic MetastasisLymph NodesMaleMiddle AgedNeoplasm ProteinsNeoplasm Recurrence, LocalPrognosisTumor MicroenvironmentNeoplasm Proteins

Identifiers

PMID34337026
PMCPMC8292094
OpenAlexW3182227357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.